BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen L, Li B, Yang WC, He JL, Li NY, Hu J, He YF, Yu S, Zhao Z, Luo P. A dominant CD4(+) T-cell response to Helicobacter pylori reduces risk for gastric disease in humans. Gastroenterology. 2013;144:591-600. [PMID: 23232294 DOI: 10.1053/j.gastro.2012.12.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Xie J, Wen J, Chen C, Luo M, Hu B, Wu D, Ye J, Lin Y, Ning L, Ning Y, Li Y. Notch 1 Is Involved in CD4+ T Cell Differentiation Into Th1 Subtype During Helicobacter pylori Infection. Front Cell Infect Microbiol 2020;10:575271. [PMID: 33224898 DOI: 10.3389/fcimb.2020.575271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Yang W, Sun H, Sun H, Yuan H, Li B, Li H, Hu J, Yang Y, Zou Q, Guo H, Wu C, Chen L. Intranasal immunization with immunodominant epitope peptides derived from HpaA conjugated with CpG adjuvant protected mice against Helicobacter pylori infection. Vaccine 2018;36:6301-6. [DOI: 10.1016/j.vaccine.2018.09.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
3 Mao FY, Lv YP, Hao CJ, Teng YS, Liu YG, Cheng P, Yang SM, Chen W, Liu T, Zou QM, Xie R, Xu JY, Zhuang Y. Helicobacter pylori-Induced Rev-erbα Fosters Gastric Bacteria Colonization by Impairing Host Innate and Adaptive Defense. Cell Mol Gastroenterol Hepatol 2021;12:395-425. [PMID: 33676046 DOI: 10.1016/j.jcmgh.2021.02.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pachathundikandi SK, Tegtmeyer N, Backert S. Signal transduction of Helicobacter pylori during interaction with host cell protein receptors of epithelial and immune cells. Gut Microbes. 2013;4:454-474. [PMID: 24280762 DOI: 10.4161/gmic.27001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
5 Hornburg D, Kruse T, Anderl F, Daschkin C, Semper RP, Klar K, Guenther A, Mejías-Luque R, Schneiderhan-Marra N, Mann M, Meissner F, Gerhard M. A mass spectrometry guided approach for the identification of novel vaccine candidates in gram-negative pathogens. Sci Rep 2019;9:17401. [PMID: 31758014 DOI: 10.1038/s41598-019-53493-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yang J, Dai LX, Pan X, Wang H, Li B, Zhu J, Li MY, Shi XL, Wang BN. Protection against Helicobacter pylori infection in BALB/c mice by oral administration of multi-epitope vaccine of CTB-UreI-UreB. Pathog Dis. 2015;73:pii ftv026. [PMID: 25846576 DOI: 10.1093/femspd/ftv026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ning Y, Ye J, Wen J, Wu D, Chen Z, Lin Y, Hu B, Luo M, Luo J, Ning L, Li Y. Identification of Two Lpp20 CD4+ T Cell Epitopes in Helicobacter pylori-Infected Subjects. Front Microbiol 2018;9:884. [PMID: 29875738 DOI: 10.3389/fmicb.2018.00884] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
8 Nezafat N, Eslami M, Negahdaripour M, Rahbar MR, Ghasemi Y. Designing an efficient multi-epitope oral vaccine against Helicobacter pylori using immunoinformatics and structural vaccinology approaches. Mol Biosyst 2017;13:699-713. [PMID: 28194462 DOI: 10.1039/c6mb00772d] [Cited by in Crossref: 55] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
9 Nordstrom EM, Keniston A, Baouchi F, Martinez-Camacho A. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety. Eur J Gastroenterol Hepatol 2017;29:10-6. [PMID: 27755117 DOI: 10.1097/MEG.0000000000000755] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
10 Koch M, Meyer TF, Moss SF. Inflammation, immunity, vaccines for Helicobacter pylori infection. Helicobacter. 2013;18 Suppl 1:18-23. [PMID: 24011240 DOI: 10.1111/hel.12073] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
11 Yang HJ, Zhang JY, Wei C, Yang LY, Zuo QF, Zhuang Y, Feng YJ, Srinivas S, Zeng H, Zou QM. Immunisation With Immunodominant Linear B Cell Epitopes Vaccine of Manganese Transport Protein C Confers Protection against Staphylococcus aureus Infection. PLoS One 2016;11:e0149638. [PMID: 26895191 DOI: 10.1371/journal.pone.0149638] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
12 Zhang S, Desrosiers J, Aponte-Pieras JR, DaSilva K, Fast LD, Terry F, Martin WD, De Groot AS, Moise L, Moss SF. Human immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods. PLoS One 2014;9:e94974. [PMID: 24740005 DOI: 10.1371/journal.pone.0094974] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
13 De Groot AS, Einck L, Moise L, Chambers M, Ballantyne J, Malone RW, Ardito M, Martin W. Making vaccines "on demand": a potential solution for emerging pathogens and biodefense? Hum Vaccin Immunother 2013;9:1877-84. [PMID: 23877094 DOI: 10.4161/hv.25611] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
14 Malfertheiner P, Venerito M, Selgrad M. Helicobacter pylori infection: selected aspects in clinical management. Curr Opin Gastroenterol. 2013;29:669-675. [PMID: 24100726 DOI: 10.1097/mog.0b013e328365d443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
15 Zendehdel A, Roham M. Biological evidence of the relationship between Helicobacter pylori and associated extragastric diseases. J Cell Biochem 2019;120:12128-40. [DOI: 10.1002/jcb.28681] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Chen L, Anthony A, Oveissi S, Huang M, Zanker D, Xiao K, Wu C, Zou Q, Chen W. Broad-Based CD4+ T Cell Responses to Influenza A Virus in a Healthy Individual Who Lacks Typical Immunodominance Hierarchy. Front Immunol 2017;8:375. [PMID: 28421076 DOI: 10.3389/fimmu.2017.00375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
17 Zhang J, Jing H, Luo P, Zhang X, Zou Q. Design, implementation, and outcomes of an elective course on preliminary structural biology for undergraduate students majoring in biotechnology. Biochem Mol Biol Educ 2020;48:168-74. [PMID: 31663671 DOI: 10.1002/bmb.21312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Lérias JR, Paraschoudi G, de Sousa E, Martins J, Condeço C, Figueiredo N, Carvalho C, Dodoo E, Castillo-Martin M, Beltrán A, Ligeiro D, Rao M, Zumla A, Maeurer M. Microbes as Master Immunomodulators: Immunopathology, Cancer and Personalized Immunotherapies. Front Cell Dev Biol 2019;7:362. [PMID: 32039196 DOI: 10.3389/fcell.2019.00362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
19 Yang Y, Chen L, Sun HW, Guo H, Song Z, You Y, Yang LY, Tong YN, Gao JN, Zeng H, Yang WC, Zou QM. Epitope-loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against Helicobacter pylori. J Nanobiotechnology 2019;17:6. [PMID: 30660182 DOI: 10.1186/s12951-019-0441-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
20 Xie W, Zhao W, Zou Z, Kong L, Yang L. Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice. Helicobacter 2021;26. [DOI: 10.1111/hel.12807] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Bagheri N, Salimzadeh L, Shirzad H. The role of T helper 1-cell response in Helicobacter pylori-infection. Microb Pathog 2018;123:1-8. [PMID: 29936093 DOI: 10.1016/j.micpath.2018.06.033] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
22 Sun H, Yuan H, Tan R, Li B, Guo G, Zhang J, Jing H, Qin Y, Zhao Z, Zou Q, Wu C. Immunodominant antigens that induce Th1 and Th17 responses protect mice against Helicobacter pylori infection. Oncotarget 2018;9:12050-63. [PMID: 29552292 DOI: 10.18632/oncotarget.23927] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
23 Chen L, Zanker D, Xiao K, Wu C, Zou Q, Chen W. Immunodominant CD4+ T-cell responses to influenza A virus in healthy individuals focus on matrix 1 and nucleoprotein. J Virol 2014;88:11760-73. [PMID: 25078703 DOI: 10.1128/JVI.01631-14] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
24 Guo L, Hong D, Wang S, Zhang F, Tang F, Wu T, Chu Y, Liu H, He M, Yang H, Yin R, Liu K. Therapeutic Protection Against H. pylori Infection in Mongolian Gerbils by Oral Immunization With a Tetravalent Epitope-Based Vaccine With Polysaccharide Adjuvant. Front Immunol 2019;10:1185. [PMID: 31191547 DOI: 10.3389/fimmu.2019.01185] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
25 Matsuo Y, Kido Y, Akada J, Shiota S, Binh TT, Trang TTH, Dung HDQ, Tung PH, Tri TD, Thuan NPM, Tam LQ, Nam BC, Khien VV, Yamaoka Y. Novel CagA ELISA exhibits enhanced sensitivity of Helicobacter pylori CagA antibody. World J Gastroenterol 2017; 23(1): 48-59 [PMID: 28104980 DOI: 10.3748/wjg.v23.i1.48] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
26 Hu J, Chen L, Yang W, Li B, Sun H, Wei S, He Y, Zhao Z, Yang S, Zou Q, Chen W, Guo H, Wu C. Systematic identification of immunodominant CD4+ T cell responses to HpaA in Helicobacter pylori infected individuals. Oncotarget 2016;7:54380-91. [PMID: 27509059 DOI: 10.18632/oncotarget.11092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]